TY - JOUR
T1 - Assessing the benefits of lipid-lowering therapy
AU - Gotto, Antonio M.
PY - 1998
Y1 - 1998
N2 - In recent years, a substantial body of evidence has emerged to support the use of lipid-lowering therapy in the prevention of coronary artery disease, and many physician groups have endorsed the management of dyslipidemia in at-risk patients. An important consideration in such endorsements has been the issue of the safety of lipid intervention; many early primary- and secondary-prevention studies reported either no reduction in all-cause mortality rates or an increase in non-coronary artery disease mortality rates in treated patients. These observations raised serious concerns about the safety of such therapy. However, 2 landmark studies, the Scandinavian Simvastatin Survival Study (45) and the West of Scotland Coronary Prevention Study (WOSCOPS), have contributed greatly to alleviating these concerns. In this article, a review of the epidemiologic evidence supporting the use of lipid modification will be presented, including important trials and meta-analyses, and the cost-effectiveness of lipid-modifying treatment will be discussed.
AB - In recent years, a substantial body of evidence has emerged to support the use of lipid-lowering therapy in the prevention of coronary artery disease, and many physician groups have endorsed the management of dyslipidemia in at-risk patients. An important consideration in such endorsements has been the issue of the safety of lipid intervention; many early primary- and secondary-prevention studies reported either no reduction in all-cause mortality rates or an increase in non-coronary artery disease mortality rates in treated patients. These observations raised serious concerns about the safety of such therapy. However, 2 landmark studies, the Scandinavian Simvastatin Survival Study (45) and the West of Scotland Coronary Prevention Study (WOSCOPS), have contributed greatly to alleviating these concerns. In this article, a review of the epidemiologic evidence supporting the use of lipid modification will be presented, including important trials and meta-analyses, and the cost-effectiveness of lipid-modifying treatment will be discussed.
UR - http://www.scopus.com/inward/record.url?scp=0032563784&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032563784&partnerID=8YFLogxK
U2 - 10.1016/S0002-9149(98)00526-8
DO - 10.1016/S0002-9149(98)00526-8
M3 - Article
C2 - 9766341
AN - SCOPUS:0032563784
VL - 82
SP - 2M-4M
JO - American Journal of Cardiology
JF - American Journal of Cardiology
SN - 0002-9149
IS - 6 SUPPL. 1
ER -